1. The Emerging Facets of Non-Cancerous Warburg Effect
- Author
-
Alyaa M. Abdel-Haleem, Nathan E. Lewis, Neema Jamshidi, Katsuhiko Mineta, Xin Gao, and Takashi Gojobori
- Subjects
0301 basic medicine ,Cell type ,Angiogenesis ,Endocrinology, Diabetes and Metabolism ,Clinical Sciences ,malaria ,Context (language use) ,constraint-based metabolic modeling ,Biology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Vaccine Related ,03 medical and health sciences ,angiogenesis ,Endocrinology ,immune cells ,medicine ,cancer ,Repurposing ,Nutrition and Dietetics ,lcsh:RC648-665 ,Cancer ,medicine.disease ,pluripotency ,Warburg effect ,3. Good health ,Cell biology ,030104 developmental biology ,Infectious Diseases ,Good Health and Well Being ,Anaerobic glycolysis ,Perspective ,Identification (biology) ,Neuroscience ,rapid proliferation - Abstract
The Warburg effect (WE), or aerobic glycolysis, is commonly recognized as a hallmark of cancer and has been extensively studied for potential anti-cancer therapeutics development. Beyond cancer, the WE plays an important role in many other cell types involved in immunity, angiogenesis, pluripotency, and infection by pathogens (e.g., malaria). Here, we review the WE in non-cancerous context as a "hallmark of rapid proliferation." We observe that the WE operates in rapidly dividing cells in normal and pathological states that are triggered by internal and external cues. Aerobic glycolysis is also the preferred metabolic program in the cases when robust transient responses are needed. We aim to draw attention to the potential of computational modeling approaches in systematic characterization of common metabolic features beyond the WE across physiological and pathological conditions. Identification of metabolic commonalities across various diseases may lead to successful repurposing of drugs and biomarkers.
- Published
- 2017
- Full Text
- View/download PDF